Organisation paid for research Program year 2025 Source: CMS Open Payments

Valkyrie Global, Inc

Neither a doctor nor a teaching hospital

Research payments

$709,455

12 payments

Through program year 2025, Valkyrie Global, Inc is reported as receiving $709,455 in research payments, across 12 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$261,794	5
2024	Research	$297,672	5
2023	Research	$149,989	2

Breakdown

Who paid Research payments · program years 2023–2025

E.R. Squibb & Sons, L.L.C. $581,922 9 payments
Mirati Therapeutics, Inc. $70,494 2 payments
AstraZeneca UK Limited $57,039 1 payment

Studies the money was for Research payments · program years 2023–2025

Phase I/IIA Dose Esc/Exp KRAS mut G12Ci (R/R naive) BMS run - Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors $187,846 2 payments
A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors $144,975 1 payment
Phase I JNK1 Monotherapy/Combination - A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors $94,809 2 payments
Phase I/Ib FIH Monotherapy/Combination - A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors $94,512 1 payment
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 $70,494 2 payments
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors $58,255 2 payments
a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 $57,039 1 payment
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment $1,525 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.